Country: কানাডা
ভাষা: ইংরেজি
সূত্র: Health Canada
DESLORATADINE
TEVA CANADA LIMITED
R06AX27
DESLORATADINE
5MG
TABLET
DESLORATADINE 5MG
ORAL
10
OTC
SECOND GENERATION ANTIHISTAMINES
Active ingredient group (AIG) number: 0143961001; AHFS:
CANCELLED POST MARKET
2020-05-11
_ _ _ALLERNIX MULTI SYMPTOM _ _Page 1 of 36_ PRODUCT MONOGRAPH ALLERNIX MULTI SYMPTOM Desloratadine Tablets 5 mg HISTAMINE H 1 -RECEPTOR ANTAGONIST Teva Canada Limited 30 Novopharm Court Toronto, Ontario Canada M1B 2K9 www.tevacanada.com Date of Preparation: April 3, 2013 Submission Control No: 163170 _ _ _ALLERNIX MULTI SYMPTOM _ _Page 2 of 36_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ........................................................ 3 SUMMARY PRODUCT INFORMATION ....................................................................... 3 INDICATIONS AND CLINICAL USE ............................................................................. 3 CONTRAINDICATIONS .................................................................................................. 3 WARNINGS AND PRECAUTIONS ................................................................................. 3 ADVERSE REACTIONS ................................................................................................... 5 DRUG INTERACTIONS ................................................................................................... 6 DOSAGE AND ADMINISTRATION ............................................................................... 7 OVERDOSAGE ................................................................................................................. 7 ACTION AND CLINICAL PHARMACOLOGY ............................................................. 7 STORAGE AND STABILITY ......................................................................................... 10 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................ 11 PART II: SCIENTIFIC INFORMATION .............................................................................. 12 PHARMACEUTICAL INFORMATION ......................................................................... 12 CLINICAL TRIALS ......................................................................................................... 13 DETAILED PHARMACOLOGY .... সম্পূর্ণ নথি পড়ুন